Search results
Showing 2656 to 2670 of 8936 results
MRI-guided focused ultrasound thalamotomy for treatment-resistant essential tremor
In development Reference number: GID-IPG10441 Expected publication date: TBC
Itopride hydrochloride for treating gastrointestinal symptoms of functional dyspepsia [ID6745]
Awaiting development Reference number: GID-TA11979 Expected publication date: TBC
Finerenone for treating heart failure with preserved or mildly reduced ejection fraction [ID6514]
In development Reference number: GID-TA11651 Expected publication date: TBC
Fertility problems: assessment and treatment - update 1 and 2
In development Reference number: GID-NG10263 Expected publication date: 31 March 2026
In development Reference number: GID-IPG10216 Expected publication date: TBC
Gene expression profiling tests for estimating risk in newly diagnosed multiple myeloma
In development Reference number: GID-HTG10153 Expected publication date: TBC
In development Reference number: GID-TA11385 Expected publication date: TBC
Osteoporosis: risk assessment, treatment, and fragility fracture prevention (update)
In development Reference number: GID-NG10216 Expected publication date: 15 July 2026
In development Reference number: GID-TA11817 Expected publication date: 09 July 2026
In development Reference number: GID-HTE10080 Expected publication date: 03 February 2027
Tofersen for treating amyotrophic lateral sclerosis caused by SOD1 gene mutations [ID3767]
In development Reference number: GID-HST10062 Expected publication date: TBC
We are listening to your views on this Highly specialised technology. Comments close 24 February 2026.
Summary of the evidence on rituximab (MabThera) for treating skin involvement in systemic sclerosis to inform local NHS planning and decision-making
Narcolepsy with or without cataplexy in adults: pitolisant (ES8)
Summary on the evidence on pitolisant for treating narcolepsy with or without cataplexy to inform local NHS planning and decision-making
Clostridium difficile infection: risk with broad-spectrum antibiotics (ESMPB1)
Summary of the evidence on the risk of using broad-specturm antibiotics associated with clostridium difficile infection